StockData

Tandem Diabetes Care vs UFP Technologies

TNDM and UFPT side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How TNDM and UFPT compare

UFP Technologies is the larger company, worth 1.8 times as much as Tandem Diabetes Care ($2.3B against $1.3B).

UFP Technologies grew revenue faster over the last twelve months (7.3% versus 4.0% for Tandem Diabetes Care).

UFP Technologies keeps more of each dollar of sales as profit, with a net margin of 11.4% compared with −6.1% at Tandem Diabetes Care.

UFP Technologies scores higher on the StockData Score (13 against 6 for Tandem Diabetes Care), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricTNDMUFPT
Size and price
Market cap$1.3B$2.3B
Share price$18.48$298.54
Change, 1 year5.4%27.4%
Change, 5 years−85.7%331%
Beta (5Y)0.791.27
Employees500K4,846
StockData Score
Total score613 (better)
Valuation score2 (better)0
Growth score12 (better)
Performance score26 (better)
Health score15 (better)
Dividend score00
Valuation
P/E–32.2×
P/S1.2× (better)3.7×
P/B9.9×5.0× (better)
EV/EBITDA–25.1×
PEG–1.88
FCF yield−2.1%–
Fair value$24.16$241.83
Margin of safety23.5% (better)−23.4%
Growth
Revenue growth (TTM)4.0%7.3% (better)
Revenue growth, 5Y average15.3%27.4% (better)
Net income growth (TTM)–7.7%
EPS growth (TTM)–7.5%
EPS growth, 5Y average–37.7%
Profitability
Gross margin56.0% (better)28.5%
Operating margin−4.4%15.3% (better)
Net margin−6.1%11.4% (better)
FCF margin−2.6%–
Return on equity−48.0%17.1% (better)
Return on invested capital−17.9%14.2% (better)
Financial health
Debt / equity4.620.25 (better)
Net debt / EBITDA–1.12
Interest coverage−5.2×12.4× (better)
Current ratio3.18 (better)3.00
Altman Z-score0.538.84 (better)
Piotroski F-score35 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions113%123%
Held by insiders1.2%4.5%
Insider net buying, 12 months−$36.9K (better)−$13.6M
Short interest, % of float23.5%12.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.